{"product_id":"resistance-to-targeted-therapies-in-multiple-myeloma-clinical","title":"Resistance to Targeted Therapies in Multiple Myeloma - Clinical","description":"\u003cp\u003eIn this review of Resistance to Targeted Therapies in Multiple Myeloma, the authors present a focused look at why targeted treatments fail as disease progresses and how newer agents attempt to overcome that resistance. The book is most useful for clinicians, oncology fellows, and researchers who need a concise, clinically oriented summary of current and emerging targeted approaches in multiple myeloma. The single biggest reason to read it is its practical synthesis of approved classes and investigational options, helping readers connect mechanisms of resistance with therapeutic strategies.\u003c\/p\u003e\u003ch2\u003eKey Features\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eClear overview of approved classes:\u003c\/strong\u003e Describes Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies and their roles in current treatment algorithms.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMechanisms of resistance explained:\u003c\/strong\u003e Links how disease progression and molecular changes lead to refractory disease, aiding clinical decision making.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDiscussion of later-generation agents:\u003c\/strong\u003e Summarizes second and third generation drugs developed to overcome resistance and their distinct mechanisms of action.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCoverage of emerging therapies:\u003c\/strong\u003e Reviews CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors that are in clinical trials.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eClinically focused synthesis:\u003c\/strong\u003e Emphasizes practical implications for sequencing targeted therapies across disease stages rather than exhaustive preclinical detail.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eWho It's For\u003c\/h2\u003e\u003cp\u003eThis book is aimed at oncologists, hematologists, oncology fellows and clinical researchers who need a compact reference on targeted therapy resistance in multiple myeloma. The emphasis on approved drug classes and trial-stage approaches makes it a useful bridge between bench science and bedside decisions.\u003c\/p\u003e\u003cp\u003eNon-specialist readers seeking a patient-oriented guide or deeply technical molecular biology may want a different text; this volume assumes familiarity with standard multiple myeloma therapies and clinical terminology.\u003c\/p\u003e\u003ch2\u003ePros \u0026amp; Cons\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003ePros\u003c\/strong\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eConcise synthesis of \u003cstrong\u003eproteasome inhibitors\u003c\/strong\u003e, immunomodulators and monoclonal antibodies and how they are used clinically.\u003c\/li\u003e\n\u003cli\u003eHelpful explanation of why patients develop refractory disease, linking mechanisms to practice.\u003c\/li\u003e\n\u003cli\u003eUseful summary of promising investigational options such as CAR-T and bi-specific antibodies for readers tracking trials.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003eCons\u003c\/strong\u003e\u003c\/p\u003e\u003cul\u003e\u003cli\u003eNot a deep molecular textbook, so researchers seeking exhaustive bench-level detail may find the coverage high level.\u003c\/li\u003e\u003c\/ul\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eTitle\u003c\/td\u003e\n\u003ctd\u003eResistance to Targeted Therapies in Multiple Myeloma\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeries\u003c\/td\u003e\n\u003ctd\u003eResistance to Targeted Anti-Cancer Therapeutics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuthors\u003c\/td\u003e\n\u003ctd\u003eSilvia CW Ling, Steven Trieu\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary topics\u003c\/td\u003e\n\u003ctd\u003eProteasome Inhibitors; Immunomodulatory Drugs; Monoclonal Antibodies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestigational therapies covered\u003c\/td\u003e\n\u003ctd\u003eCAR-T cells; bi-specific antibodies; vaccines; ubiquitin ligase inhibitors; BCL-2 inhibitors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical focus\u003c\/td\u003e\n\u003ctd\u003eMechanisms of resistance and therapeutic sequencing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\u003ch2\u003eOur Verdict\u003c\/h2\u003e\u003cp\u003eResistance to Targeted Therapies in Multiple Myeloma is a compact, clinically minded review that helps practitioners connect mechanisms of resistance with real-world treatment choices. It is good value for oncologists and researchers who want a practical update on approved classes and emerging targeted options without wading through exhaustive bench science.\u003c\/p\u003e\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eDoes this book cover CAR-T therapies?\u003c\/strong\u003e\u003cbr\u003eYes. It reviews CAR-T cells alongside other investigational approaches such as bi-specific antibodies and vaccines.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eIs the focus clinical or basic science?\u003c\/strong\u003e\u003cbr\u003eThe emphasis is clinical, explaining resistance mechanisms in the context of therapeutic sequencing and approved drug classes.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWho are the intended readers?\u003c\/strong\u003e\u003cbr\u003eThe intended audience is clinicians, oncology fellows and clinical researchers interested in targeted therapies for multiple myeloma.\u003c\/p\u003e","brand":"Silvia CW Ling, Steven Trieu","offers":[{"title":"Default Title","offer_id":48257829732571,"sku":"3030734420","price":144.68,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0724\/1043\/1707\/files\/61Yp_MHAwgL._SL1254.jpg?v=1778305021","url":"https:\/\/gearmusthave.com\/products\/resistance-to-targeted-therapies-in-multiple-myeloma-clinical","provider":"GearMustHave","version":"1.0","type":"link"}